EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic and clinical heterogeneity of PD1 and PD-L1- immunohistochemical scores in endometrial cancers

L Proppe, T Jagomast, S Beume, F Köster, K Bräutigam, A Rody, S Perner, F Hemptenmacher, J Ribbat-Idel, L C Hanker

Archives of Gynecology and Obstetrics · 2025

DOI: 10.1007/s00404-024-07862-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Gynecology and Obstetrics, 2025. Verfasst von L Proppe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Campus-Lübeck, Lübeck, Germany. louisa.proppe@gmail.com. Hauptthemen laut MEDLINE: Endometrial Neoplasms, B7-H1 Antigen, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Schleswig-Holstein - Campus Lübeck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

PD1/PD-L1 inhibition (ICi) has recently become a new standard of care for patients with advanced MMR-deficient (MMRd) endometrial cancers. Nevertheless, response to immunotherapy is more complex than the presence of a single biomarker and therefore it remains challenging to predict patients response to ICi beyond MMRd tumors. Elevated PD-L1 expression (CPS ≥ 1) is often used as a prognostic marker as well as a predictive biomarker of response to ICi in different tumor types. In a retrospective, patient derived study, we analyzed PD1- and PD-L1 staining and correlated the results of different scores to clinical data to evaluate the prognostic impact of these scores. Materials and methods Immunohistochemical analysis of the receptor PD1 and the receptor ligand PD-L1 were performed on TMAs of primary paraffin‑embedded tumor samples. All patients were treated for primary endometrial cancer in the Department of Gynecology and Obstetrics, University Medical Center Schleswig–Holstein, Campus-Lübeck, Germany between the years 2006–2018. The evaluation and determination of the tumor proportion scoring (TPS), the combined positive score (CPS) and the immune cell scoring (IC) was automatically assessed semi-quantitatively, and results were correlated with clinicopathological characteristics and survival.

Results

130 samples were evaluable and 64% showed a positivity (IC > 0) for the receptor PD1 and 56% for the receptor ligand PD-L1. Patients with a PD1 IC Score ≥ 1 showed a significant longer disease-free survival of 140 months (95% confidence interval (CI): 124–158) compared to patients with a lower IC < 1 for PD1 of 89 months (95% confidence interval (CI): 69–110); p = 0.017). Furthermore, the disease-free survival for patients with a CPS ≥ 5 for PD1 was longer (153.7 months (95% confidence interval (CI): 134–173.6) vs. 98.6 months (95% confidence interval (CI): 83–114); p = 0.036). Additionally, a PD1 CPS ≥ 5 showed a better overall survival but the result was not statistically significant. No difference in survival was found between patients with PD-L1 higher or lower than CPS 5.

Conclusion

In this study we pointed out that there are significant clinical differences among several immunohistochemical scoring systems. In our trial, a PD1-positivity with CPS ≥ 5 and IC ≥ 1 were significantly associated to a better disease-free survival while there was no association with TPS. The PD1-IC scoring was associated with MMRd while the TPS scoring was not. Therefore, PD1-IC could be more appropriate for endometrial carcinomas compared to TPS and could also add prognostic information beside the more established PD-L1-staining. Further prospective studies are needed for a validation of these scores in combination with other biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsB7-H1 AntigenProgrammed Cell Death 1 ReceptorHumansFemaleRetrospective StudiesMiddle AgedImmunohistochemistryPrognosisAgedBiomarkers, TumorAdultAged, 80 and overImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Endometrial cancerImmunohistochemistryMolecular subgroupsPD1-inhibition

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorCD274 protein, humanPDCD1 protein, humanBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Campus-Lübeck, Lübeck, Germany. louisa.proppe@gmail.com.
  • Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. louisa.proppe@gmail.com.
  • Institute of Pathology, University of Luebeck, Luebeck, Germany.
  • Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Campus-Lübeck, Lübeck, Germany.
  • Department of Gynecology and Obstetrics, University Medical Center, Muenster, Germany.

Förderung

  • Universitätsklinikum Schleswig-Holstein - Campus Lübeck

Zitieren

APA

Proppe, L., Jagomast, T., Beume, S., Köster, F., Bräutigam, K., Rody, A., Perner, S., Hemptenmacher, F., Ribbat-Idel, J., & Hanker, L. C. (2025). Prognostic and clinical heterogeneity of PD1 and PD-L1- immunohistochemical scores in endometrial cancers. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-024-07862-y

Vancouver

Proppe L, Jagomast T, Beume S, Köster F, Bräutigam K, Rody A, et al. Prognostic and clinical heterogeneity of PD1 and PD-L1- immunohistochemical scores in endometrial cancers. Archives of Gynecology and Obstetrics. 2025. doi:10.1007/s00404-024-07862-y

BibTeX
@article{Proppe2025,
  author = {Proppe, L and Jagomast, T and Beume, S and Köster, F and Bräutigam, K and Rody, A and Perner, S and Hemptenmacher, F and Ribbat-Idel, J and Hanker, L C},
  title = {Prognostic and clinical heterogeneity of PD1 and PD-L1- immunohistochemical scores in endometrial cancers},
  journal = {Archives of Gynecology and Obstetrics},
  year = {2025},
  doi = {10.1007/s00404-024-07862-y}
}
Kostenlos starten →